Comparison of the disease activity score using erythrocyte sedimentation rate and C-reactive protein in African Americans with rheumatoid arthritis

Journal of Rheumatology

Volumn 40, Issue 11, 2013, Pages 1812-1822

  Tamhane, Ashutosh ^a   Redden, David T ^a   McGwin Jr , Gerald ^a   Brown, Elizabeth E ^a   Westfall, Andrew O ^a   Reynolds IV, Richard J ^a   Hughes, Laura B ^a   Conn, Doyt L ^b   Callahan, Leigh F ^c   Jonas, Beth L ^c   Smith, Edwin A ^d   Brasington Jr , Richard D ^e   Moreland, Larry W ^f   Bridges Jr , S Louis ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e WASHINGTON UNIVERSITY   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

AFRICAN AMERICANS; DISEASE ACTIVITY SCORE 28; RHEUMATOID ARTHRITIS

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; ARTICLE; DAS28; DISEASE ACTIVITY; DISEASE DURATION; DISEASE REGISTRY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INTERMETHOD COMPARISON; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN DETERMINATION; RHEUMATOID ARTHRITIS; SEX DIFFERENCE;

AFRICAN AMERICANS; DISEASE ACTIVITY SCORE 28; RHEUMATOID ARTHRITIS;

ADULT; AFRICAN AMERICANS; AGED; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 84887456284     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121225     Document Type: Article

References (53)

1. Smolen J, Aletaha D, Bijlsma J, Breedveld F, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
2. Smolen J, Breedveld F, Schiff M, Kalden J, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42:244-57.
3. Aletaha D, Nell V, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806.
4. van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
5. van der Heijde DM, van 't Hof MA, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
6. van der Heijde DM, van 't Hof MA, van Riel PL, van Leeuwen M, van Rijswijk M, van de Putte L. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992;51:177-81.
7. Fransen J, Laan R, van der Laar M, Huizinga T, van Riel PL. Influence of guideline adherence on outcome in a randomized controlled trial on the efficacy of methotrexate with folate supplementation in rheumatoid arthritis. Ann Rheum Dis 2004;63:1222-6.
8. van Gestel AM, van Riel PL. Evaluation of early rheumatoid arthritis disease activity and outcome. Baillieres Clin Rheumatol 1997;11:49-63.
9. Creemers MC, Fransen J, de Groot-Vos EH, Welsing P, Kievit W, van Riel PL. Implementation of the DAS28 as a routine assessment in daily clinical practice [abstract]. Ann Rheum Dis 2005;64 Suppl III:603.
10. Prevoo M, van Riel PL, van 't Hof M, van Rijswijk M, van Leeuwen M, Kuper H, et al. Validity and reliability of joint counts. A longitudinal study in patients with recent onset rheumatoid arthritis. Br J Rheumatol 1993;32:589-94.
11. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum 1995;38:44-8.
12. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
13. Fransen J, Moens B, Speyer I, van Riel PL. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicenter, cluster randomized controlled trial. Ann Rheum Dis 2005;64:1294-8.
14. Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Kerstens PJ, Nielen MM, Van Schaardenburg D, Speyer I, et al. DAS-driven therapy versus routine care in patients with recent onset active rheumatoid arthritis. Ann Rheum Dis 2010;69:65-9.
15. Soubrier M, Lukas C, Sibilia J, Fautrel B, Roux F, Gossec L, et al. Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis 2011; 70:611-5.
16. Saag K, Teng G, Patkar N, Anuntiyo J, Finney C, Curtis J, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84.
17. Anderson J, Caplan L, Yazdany J, Robbins M, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res 2012;64:640-7.
18. Singh J, Furst D, Bharat A, Robbins M, Neogi T, Michaud K, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39.
19. Fransen J, Welsing PM, de Keijzer RM, van Riel PL. Disease activity scores using C-reactive protein: CRP may replace ESR in the assessment of RA disease activity. Ann Rheum Dis 2004;62 Suppl 1:151.
20. Castrejón I, Ortiz AM, Toledano E, Castañeda S, Garcia-Vadillo A, Patino E, et al. Estimated cutoff points for the 28-joint disease activity score based on C-reactive protein in a longitudinal register of early arthritis. J Rheumatol 2010;37:1439-43.
21. Aletaha D, Smolen J. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23 Suppl 39:S100-8.
22. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-60.
23. Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, et al. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis 2007;66:1221-6.
24. Soubrier M, Zerkak D, Gossec L, Ayral X, Roux C, Dougados M, et al. Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice? J Rheumatol 2006;33:1243-6.
25. Bathon JM, Martin RW, Fleischmann RM, Bingham CO, Whitmore JB, Eickenhorst T. Disease activity scores using CRP versus ESR and the relationship between EULAR and ACR responses in patients with early rheumatoid arthritis (abstract). Ann Rheum Dis 2005;64 Suppl 3:173.
26. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis 2007;66:407-9.
27. Jordan M, Lumley M, Leisen J. The relationships of cognitive coping and pain control beliefs to pain and adjustment among African-American and Caucasian women with rheumatoid arthritis. Arthritis Care Res 1998;11:1180-8.
28. Iren U, Walker M, Hochman E, Brasington R. A pilot study to determine whether disability and disease activity are different in African-American and Caucasian patients with rheumatoid arthritis in St. Louis, Missouri, USA. J Rheumatol 2005;32:602-8.
29. Lambert V, Lambert C. The relationship between social support and psychological well being in rheumatoid arthritic women from two ethnic groups. Health Care Women Int 1985;6:405-14.
30. Bolen J, Schieb L, Hootman JM, Helmick CG, Theis K, Murphy LB, et al. Differences in the prevalence and severity of arthritis among racial/ethnic groups in the United States, National Health Interview Survey, 2002, 2003, and 2006. Prev Chronic Dis 2010;7:A64.
31. Szalai A, Wu J, Lange E, McCrory M, Langefeld C, Williams A, et al. Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med 2005;83:440-7.
32. Lange L, Carlson C, Hindorff L, Lange E, Walston J, Durda J, et al. Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA 2006;296:2703-11.
33. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
34. DAS score Website. [Internet. Accessed June 17, 2013.] Available from: www.das-score.nl
35. Radovits BJ, Fransen J, van Riel PL, Laan RF. Influence of age and gender on the 28-joint Disease Activity Score (DAS28) in rheumatoid arthritis. Ann Rheum Dis 2008;67:1127-31.
36. Rangnath VK, Elashoff DA, Khanna D, Park G, Peter JB, Paulus HE, et al. Age adjustment corrects for apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset of seropositive rheumatoid arthritis in younger and older patients. J Rheumatol 2005;32:1040-2.
37. Hensor EM, Emery P, Bingham SJ, Conaghan PG. Discrepancies in categorizing rheumatoid arthritis patients by DAS-28(ESR) and DAS28(CRP): can they be reduced? Rheumatology 2010;49:1521-9.
38. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37-46.
39. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
40. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005;23 Suppl 39:S93-9.
41. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-10.
42. Den Broeder AA, Creemers MC, van Gestel AM, van Riel PL. Dose titration using the Disease Activity score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha. Rheumatology 2002;41:638-42.
43. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
44. van Hulst LT, Creemers MC, Fransen J, Li LC, Grol R, Hulscher ME, et al. How to improve DAS28 use in daily clinical practice?- a pilot study of a nurse-led intervention. Rheumatology 2010;49:741-8.
45. Crowson CS, Rahman MU, Matteson EL. Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. J Rheumatol 2009;36:1606-10.
46. Graf J, Scherzer R, Grunfeld C, Imboden J. Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. PLoS One 2009;4:e6242.
47. Castrejón I, Ortiz AM, García-Vicuña R, Lopez-Bote JP, Humbría A, Carmona L, et al. Are the C-reactive protein values and erythrocyte sedimentation rate equivalent when estimating the 28-joint disease activity score in rheumatoid arthritis? Clin Exp Rheumatol 2008;26:769-75.
48. van der Cruyssen B, van Looy S, Wyns B, Westhovens R, Durez P, van den Bosch F, et al. DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther 2002;7:R1063-71.
49. van Riel P, Fransen J. DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis. Arthritis Res Ther 2005;7:189-90.
50. Lindsay K, Ibrahim G, Sokoll K, Tripathi M, Melsom RD, Helliwell PS. The composite DAS score is impractical to use in daily practice. J Clin Rheumatol 2009;15:223-5.
51. Ward MM. Relative sensitivity to change of the erythrocyte sedimentation rate and serum C-reactive protein concentration in rheumatoid arthritis. J Rheumatol 2004;31:884-95.
52. Paulus HE, Brahn E. Is erythrocyte sedimentation rate the preferable measure of the acute phase response in rheumatoid arthritis? J Rheumatol 2004;31:838-40.
53. Bridges S, Hughes L, Mikuls T, Howard G, Tiwari H, Alarcon G, et al. Early rheumatoid arthritis in African-Americans: The CLEAR Registry. Clin Exp Rheumatol 2003;21 Suppl 31:S138-45.